BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

LifeScience Clinical & Diagnostic

TiumBio Initiates Phase 1b Trial for New Hemophilia Treatment TU7710

TiumBio Co., Ltd., a trailblazer in the biopharmaceutical landscape, dedicated to crafting groundbreaking therapies for rare and untreatabl...

March 27, 2024 | News

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL

Takeda Receives FDA Approval for ICLUSIG as a First-Line Treatment in Ph+ ALL Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK) is plea...

March 25, 2024 | News

AriBio Secures Exclusive $770M Deal for Alzheimer's Drug in China

AriBio Co., Ltd. (AriBio), announces signing of exclusive marketing rights for AR1001, an investigational drug for early Alzheimer’s disease, in Chin...

March 25, 2024 | News

Australia Grants AUD 17M to TB Alliance for Innovative Treatments

The Australian Government, through the Partnerships for a Healthy Region initiative, has announced a new AUD 17 million grant to support work with TB Allia...

March 25, 2024 | News

Lynk Pharmaceuticals Initiates Pivotal Phase III Trial for Groundbreaking Atopic Dermatitis Treatment

Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, announced that it...

March 22, 2024 | News

Bayer AG Partners with Thermo Fisher for Breakthrough in Cancer Treatment Diagnostics

Development of next-generation sequencing companion diagnostics (CDx) Goal is to help increase patient access to Bayer’s precision cancer therapie...

March 20, 2024 | News

AstraZeneca Acquires Fusion Pharmaceuticals in a $2 Billion Upfront Deal

AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-gene...

March 19, 2024 | News

Asieris Announces Breakthrough Non-Surgical Treatment for Cervical High-Grade Squamous Intraepithelial Lesion

Asieris Pharmaceuticals (Stock Code: 688176.SH), a trailblazer in the global biopharmaceutical industry with a focus on genitourinary tumors and related di...

March 19, 2024 | News

KeChow Pharma's Tunlametinib Receives Historic Approval in China for Advanced Melanoma Treatment

KeChow Pharma, a commercial-stage pharmaceutical company focused on developing and commercializing differentiated small molecule therapeutics for cancer, t...

March 19, 2024 | News

Revvity Launches Revolutionary Newborn Sequencing Workflow to Advance Rare Disease Diagnosis

Revvity, Inc., a pioneering force in genomic sequencing technology, has announced the launch of a groundbreaking "sample-to-answer" workflow tailored speci...

March 18, 2024 | News

CStone's Sugemalimab Granted Historic Approval in China for Gastric Cancer Treatment

CStone Pharmaceuticals has achieved a significant milestone with the approval of sugemalimab (Cejemly®) by the National Medical Products Administration...

March 18, 2024 | News

BeiGene's TEVIMBRA Wins FDA Nod for Advanced Esophageal Cancer Post-Chemotherapy

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has app...

March 15, 2024 | News

Almirall and Eloxx Pharmaceuticals Forge Exclusive Global License Agreement for Rare Disease Treatment ZKN-013

Almirall, S.A. (BME:ALM), a global biopharmaceutical company, and Eloxx Pharmaceuticals, Inc. (OTC: ELOX), a clinical-stage biopharmaceutical innovator, ha...

March 14, 2024 | News

TiumBio Advances TU2218 in Phase 2a Trial with Pembrolizumab for Three Cancer Types

TiumBio will pursue three indications for the TU2218 combination clinical trial with pembrolizumab TU2218 demonstrated a favorable safety and a synerget...

March 12, 2024 | News

Stay Connected